In the trial, Bevespi Aerosphere, a rival COPD treatment to GSK’s product, showed non-inferiority to umeclidinium/vilanterol on peak forced expiratory volume in one second (FEV1) but and failed
NK is a rare and progressive eye disease, which may result in corneal scarring and vision loss. The FDA has approved Oxervate eye drops for use in adults
These amendments accelerate timelines for the anticipated primary completion dates of both trials. ARCHES is a randomized Phase 3 study evaluating the efficacy and safety of enzalutamide plus
The partnership will assess Rexahn’s RX-5902 and Merck’s anti-PD-1 therapy in a phase 2 study in patients with metastatic triple negative breast cancer (TNBC). The trial has been
The agreement marks a first for CCAB as part of its new business strategy, which aims to attract investment to create successful life sciences companies in Canada. The
AC Immune CEO Prof Andrea Pfeifer said: “We are delighted with the progress of ACI-24, the anti-Abeta vaccine, derived from our proprietary SupraAntigenTM platform. In addition to the
The approval follows the priority review of Alecensa in China, just eight and nine months after European Medicines Agency (EMA) and US Food and Drug Administration (FDA) approvals,
Approval for this indication has been granted under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be
The partnership will carry out clinical trial to explore the potential of combination therapy with AbbVie’s venetoclax and Tolero’s investigational agent alvocidib to treat relapsed/refractory AML. Alvocidib is
Through a multi-phase collaboration, WuXi will leverage and evaluate Cyclica’s cloud-based proteome Ligand Express screening platform to investigate the off-target profiles of small molecules, apply Cyclica’s novel and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.